| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/11/2007 | WO2006095026A3 New soft gelatin capsules |
| 01/11/2007 | WO2006083936A3 Anti-ephb2 antibodies and methods using same |
| 01/11/2007 | WO2006079896A3 Stable polyol formulations of oxazolidinone antibacterial agents |
| 01/11/2007 | WO2006008179A3 Cyanine dyes conjugated with antibodies for the diagnosis of micrometastasis |
| 01/11/2007 | WO2006003014A3 Hydrogel polymeric conjugates of a prodrug |
| 01/11/2007 | US20070010660 G-CSF Conjugates |
| 01/11/2007 | US20070010652 Polyamino acids functionalised with at least one hydrophobic group and applications thereof particularly therapeutic applications |
| 01/11/2007 | US20070010632 Antioxidant-functionalized polymers |
| 01/11/2007 | US20070010577 Administering an emulsion of a nanoparticulate carrier containing an alpha v beta 3 integrin targeting ligand and fumagillin, TNP 470 or rapamycin that are coupled through colocalization in the nanoparticles; the antiangiogenic agent is effective at a dosage at least 56,000 fold lower than the free drug |
| 01/11/2007 | US20070010575 Intracorporeal medicaments for photodynamic treatment of disease |
| 01/11/2007 | US20070010570 Medical Compositions for Intravesical Treatment of Bladder Cancer |
| 01/11/2007 | US20070010467 Targeted double stranded rna mediated cell killing |
| 01/11/2007 | US20070010452 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 01/11/2007 | US20070010447 Methods and compounds for the treatment of mucus hypersecretion |
| 01/11/2007 | US20070010436 Remedy for cardiomyopathy |
| 01/11/2007 | US20070010425 Pharmaceutical compositions and methods for insulin treatment |
| 01/11/2007 | US20070010424 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
| 01/11/2007 | US20070010422 Improved bioavailability; for oral and intracolonic administration |
| 01/11/2007 | US20070009921 Fragments of virus protein 2 or 3 of polyoma virus as vehicles for active substances |
| 01/11/2007 | US20070009611 Treatment of wounds and compositions employed |
| 01/11/2007 | US20070009605 Encapsulation of water soluble peptides |
| 01/11/2007 | US20070009579 Polysaccharide pseudo-sponge |
| 01/11/2007 | US20070009576 Nutritionally fortified liquid composition with added value delivery systems/elements/additives |
| 01/11/2007 | US20070009575 Novel use of antisecretory factor |
| 01/11/2007 | US20070009554 Biologically active hemagglutinin from type a clostridium botulinum and methods of use |
| 01/11/2007 | US20070009541 Drug conjugate composition |
| 01/11/2007 | US20070009540 Drug conjugate composition |
| 01/11/2007 | US20070009539 a liquid and/or lyophilized mixture of buffers and humanized antibody that binds tumor antigens, chemically coupled to a maytansine derivative, used as antitumor and/or anticarcinogenic agents |
| 01/11/2007 | US20070009487 Minimal promoters and uses thereof |
| 01/11/2007 | US20070009442 Macrocyclic metal complexes and their use for the production of conjugates with biomolecules |
| 01/11/2007 | US20070009433 14094, a novel human trypsin family member and uses thereof |
| 01/11/2007 | CA2848662A1 Il-12/p40 binding proteins |
| 01/11/2007 | CA2614312A1 Drug-introduced photo-crosslinked hyaluronic acid derived gel |
| 01/11/2007 | CA2614049A1 Method of biomolecule immobilization on polymers using click-type chemistry |
| 01/11/2007 | CA2613481A1 Process for attaching effector molecules to proteins |
| 01/11/2007 | CA2613112A1 Hcv inhibitors |
| 01/11/2007 | CA2613040A1 Method for preparing a covalently cross linked oligomer of amyloid beta peptides |
| 01/11/2007 | CA2612864A1 Composition and dosage form comprising a solid or semi-solid matrix |
| 01/11/2007 | CA2612241A1 Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| 01/11/2007 | CA2611125A1 Prolonged release formulation of active principles having a ph-dependent solubility |
| 01/10/2007 | EP1741781A2 RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
| 01/10/2007 | EP1741723A1 ß-CHITIN COMPLEX AND METHOD FOR PRODUCING THE SAME |
| 01/10/2007 | EP1741450A1 Composition for medical use having improved water-solubility of peptide and metal-labeling efficiency and preparation for medical use comprising metal-labeled peptide |
| 01/10/2007 | EP1741448A1 Crosslinkable pressure-sensitive adhesive for the skin |
| 01/10/2007 | EP1741438A1 Pharmaceutical preparation containing bacterial cell wall skeleton component |
| 01/10/2007 | EP1741436A1 Strontium compound for treatment of sub-dermal soft tissue pain |
| 01/10/2007 | EP1741433A1 Pharmaceutical composition comprising an androgen |
| 01/10/2007 | EP1741426A2 Melt-extruded orally administrable opioid formulations |
| 01/10/2007 | EP1741425A2 Novel antiviral pharmaceutical composition |
| 01/10/2007 | EP1741424A2 Solid pharmaceutical dispersions with enhanced bioavailabilty |
| 01/10/2007 | EP1740946A2 Human monoclonal antibodies against cd20 |
| 01/10/2007 | EP1740605A2 Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use |
| 01/10/2007 | EP1740541A2 Therapeutic formulations of desoxyepothilones |
| 01/10/2007 | EP1740224A2 Compositions as adjuvants to improve immune responses to vaccines and methods of use |
| 01/10/2007 | EP1740219A2 Medical device with coating for capturing genetically-altered cells and methods of using same |
| 01/10/2007 | EP1740217A2 Meningococcal conjugate vaccination |
| 01/10/2007 | EP1740216A2 Antibody calicheamicin conjugates |
| 01/10/2007 | EP1740215A2 Thiopeptide conjugates for drug delivery |
| 01/10/2007 | EP1740214A2 Method of stabilizing disordered cefovecin sodium salt |
| 01/10/2007 | EP1740213A2 Liquid growth hormone formulation |
| 01/10/2007 | EP1740207A2 Antigen delivery vectors and constructs |
| 01/10/2007 | EP1740193A2 Macromolecule-containing sustained release intraocular implants and related methods |
| 01/10/2007 | EP1740191A1 Use of equol for treating skin diseases |
| 01/10/2007 | EP1740166A2 Therapeutic antimicrobial compositions and methods |
| 01/10/2007 | EP1417227B1 Peptides eefective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/10/2007 | EP1406680A4 Biofunctional fibers |
| 01/10/2007 | EP1305051A4 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
| 01/10/2007 | EP1228093B1 Improvement of peptide transport by conjugation with bile acids |
| 01/10/2007 | EP1218011B1 Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses |
| 01/10/2007 | EP1176984B1 Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates |
| 01/10/2007 | EP1054672B1 Morphine sulphate microgranules, method for making same and pharmaceutical preparations |
| 01/10/2007 | EP0866709B1 1,2,4-benzotriazine oxides formulations |
| 01/10/2007 | CN1894344A Compounds for dual photodiagnosis and therapy |
| 01/10/2007 | CN1893989A Crosslinked hyaluronic acid compositions for tissue augmentation |
| 01/10/2007 | CN1893982A Menthol-containing preparation |
| 01/10/2007 | CN1893980A Novel GLP-1 analogues linked to albumin-like agents |
| 01/10/2007 | CN1893976A Radiation therapy and medical imaging using uv emitting nanoparticles |
| 01/10/2007 | CN1893970A Beta-amyloid-analogue-cell epitop vaccine |
| 01/10/2007 | CN1893967A Leukocyte internalized peptide-drug conjugates |
| 01/10/2007 | CN1893938A 普瑞巴林组合物 Pregabalin composition |
| 01/10/2007 | CN1893931A Preparations for topical application and methods of delivering an active agent to a substrate |
| 01/10/2007 | CN1893924A Novel cationic lipopolymer as a biocompatible gene delivery agent |
| 01/10/2007 | CN1893922A Pharmaceutical oral dosage form comprising a non-steroidal anti-inflammatory drug, and having good palatability |
| 01/10/2007 | CN1893892A Pharmaceutical formulations of camptothecins and process for making same |
| 01/10/2007 | CN1891717A Chemical modification method of endostatin and its use |
| 01/10/2007 | CN1891303A Method for preparing bile acid adsorbent of beta cyclo dextrin polymer |
| 01/10/2007 | CN1891302A Drug carrier and method for preparing same |
| 01/10/2007 | CN1891301A Nano microgel, and its preparing method and use |
| 01/10/2007 | CN1891300A Benzocaine film-formed gel composition and its use |
| 01/10/2007 | CN1891299A Sugar alcohol composition for tableting |
| 01/10/2007 | CN1891298A Drug depot for parenteral drug release, in particular intravascular drug release |
| 01/10/2007 | CN1891270A Burn-empyrosis-wound-sore oil, and its compounding method and use |
| 01/10/2007 | CN1891208A Method for preparing floating-biological adhesion synergistic microparticle |
| 01/10/2007 | CN1294201C Alkyd-lactone copolymers for medical applications |
| 01/10/2007 | CN1294142C 17 beta-carbothioate 17 alpha-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 01/10/2007 | CN1294141C 6 alpha., 9 alpha-difluoro-17.alpha.-[(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
| 01/10/2007 | CN1293921C Long-term effective injection containing ethylcellulose and fatty acid ester |
| 01/10/2007 | CN1293920C Process for preparing active target-directional carrier mediated by folic acid compound mediated |
| 01/10/2007 | CN1293916C Stable insulin formulations |
| 01/10/2007 | CN1293915C Method for reducing calcified plaque buildup and cellular malfunction and for balancing ionic calcium |